Rivoceranib

Active substance Rivoceranib
Domain Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Stomach cancer
Extended indication Behandeling van vergevorderde of gemetastaseerd maagkanker 3L

Product

Manufacturer LSK BioPharma
Mechanism of action Tyrosine kinase inhibitor
Route of administration Oral
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Submission date 2020
Expected Registration 2021
Orphan drug Yes
Registration phase Clinical trials
Additional comments Fase 3 studie inmiddels afgerond.

Therapeutic value

Current treatment options Capecitabine, en in de toekomst trifluridine / tipiracil
Therapeutic value No judgement
Duration of treatment Not found
Frequency of administration 1 times a day
References NCT03042611

Expected patient volume per year

Patient volume

< 78

Market share is generally not included unless otherwise stated.

References IKNL; expertopinie
Additional comments Ongeveer 70 patiënten wordt behandeld in de 2e lijn voor gemetastaseerd adenocarcinoom van de maag of gastro-oesofageale overgang. Het aantal patiënten met een slokdarmcarcinoom die in de tweede lijn worden behandeld bedraagt ongeveer 60. In totaal zijn dit dus 130 patiënten. De inschatting is dat hiervan maximaal 60% een derde lijns behandeling krijgt (78 patiënten).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Liver cancer; Non-small cell lung cancer; Ovarian cancer
References AdisInsight
Additional comments De verwachting is echter niet dat deze indicatieuitbreidingen binnen 2 jaar zullen plaatsvinden.

Other information

There is currently no futher information available.